枸地氯雷他定联合组织胺人免疫球蛋白治疗慢性荨麻疹疗效观察.docVIP

枸地氯雷他定联合组织胺人免疫球蛋白治疗慢性荨麻疹疗效观察 　　【摘要】 目的 观察枸地氯雷他定联合组织胺人免疫球蛋白治疗慢性荨麻疹的临床疗效。方法 68例慢性荨麻疹患者， 随机分为对照组和观察组， 各34例。对照组采用口服枸地氯雷他定治疗， 观察组在对照组治疗基础上给予组织胺人免疫球蛋白皮下注射治疗。比较两组患者治疗前后的病情评分、临床疗效及复发率。结果 两组患者治疗前病情评分比较差异无统计学意义（P0.05）；治疗30 d后， 观察组患者病情评分显著低于对照组， 差异具有统计学意义（P0.05）。结论 应用枸地氯雷他定联合组织胺人免疫球蛋白治疗慢性荨麻疹疗效显著， 能够降低患者复发率， 值得推广 【关键词】 枸地氯雷他定；组织胺人免疫球蛋白；慢性荨麻疹 DOI：10.14163/j.cnki.11-5547/r.2017.12.010 【Abstract】 Objective To observe clinical effect by desloratadine citrate disodium combined with histamine human immunoglobulin in the treatment of chronic urticaria. Methods A total of 68 patients with chronic urticaria were randomly divided into control group and observation group， with 34 cases in each group. The control group received oral administration of desloratadine citrate disodium for treatment， and the observation group received additional subcutaneous injection of histamine human immunoglobulin to therapy in the control group. Comparison was made on disease scores before and after treatment， clinical effect and recurrence rate between the two groups. Results There was no statistically significant difference of disease score between the two groups before treatment （P0.05）. After 30 d of treatment， the observation group had obviously lower disease score than the control group， and the difference had statistical significance （P0.05）. Conclusion Implement of desloratadine citrate disodium combined with histamine human immunoglobulin in the treatment of chronic urticaria shows excellent curative effect， along with lowered recurrence rate in patients. It is worth promoting. 【Key words】 Desloratadine citrate disodium； Histamine human immunoglobulin； Chronic urticaria 慢性?n麻疹是皮肤科常见病， 本病病程较长， 易反复发作， 严重影响患者生活质量[1-5]。本病目前临床无特异性治疗， 常规应用H1受体拮抗剂， 通常治疗有效但易复发。本科于2014年10月～2016年8月采用组织胺人免疫球蛋白联合枸地氯雷他定片治疗慢性荨麻疹， 取得良好疗效， 现报告如下。 　　1 资料与方法 1. 1 一般资料 选择本院2014年10月～2016年8月门诊诊治的慢性荨麻疹患者68例作为研究对象。入选标准：年龄18～60岁、男女不限、诊断符合慢性荨麻疹诊断标准[6]， 自愿接受观察治疗及随访。排除标准：①孕妇及哺乳期妇女；②1周内曾用抗组胺药、4周内曾用糖皮质激素或其他免疫抑制剂治疗者；③有严重肝肾功能